Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + adefovir dipivoxil + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This is a combination therapy consisting of peginterferon alfa-2a, adefovir dipivoxil, and tenofovir disoproxil fumarate. These medications have been studied in various combinations for the treatment of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Peginterferon alfa-2a is an immunomodulator that enhances the body's immune response against viral infections. Adefovir dipivoxil and tenofovir disoproxil fumarate are both nucleotide analogs that inhibit viral DNA polymerase, preventing viral replication. Clinical studies have shown that combination therapies may be more effective than monotherapy in reducing viral load, though results vary depending on the specific combination and timing of administration.
- Brand names
- PegasysHepseraViread
- Other names
- Peg-IFN + ADV + TDFpeginterferon alfa 2a + adefovir dipivoxil + tenofovir disoproxil fumarate-Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)-chronic hepatitis B
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on peginterferon alfa-2a + adefovir dipivoxil + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + adefovir dipivoxil + tenofovir disoproxil fumarate.